Literature DB >> 22329792

Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients.

G Castaman1, A B Federici, A Tosetto, S La Marca, F Stufano, P M Mannucci, F Rodeghiero.   

Abstract

BACKGROUND: Type 2A and 2M von Willebrand disease (VWD2A and VWD2M) are characterized by the presence of a dysfunctional von Willebrand factor (VWF) and a variable bleeding tendency. So far, a head-to-head comparison of the clinical history and bleeding risk between VWD2A and VWD2M has never been provided in a prospective manner. AIM OF THE STUDY: We assessed the bleeding incidence rate and clinical characteristics in two cohorts of 17 families (46 patients) with VWD2A and 15 families (61 patients) with VWD2M prospectively followed-up for 24 months. VWF gene mutations were characterized in all of them.
RESULTS: Mean bleeding score (BS) and VWF antigen at enrollment were significantly higher in VWD2A patients (P = 0.007). No correlation between VWF activity or factor VIII levels and the severity of BS was observed. The incidence rate of spontaneous bleeding requiring treatment was 107/100 patient-years (95% CI, 88.3-131) in VWD2A compared with 40/100 patient-years (95% CI, 30-53) in VWD2M (P < 0.001). The risk of bleeding was significantly higher in patients with BS ≥ 10 at enrollment compared with those with BS 0-2. Furthermore, 54 episodes of gastrointestinal bleeding occurred in 17/46 (36.9%) VWD2A patients and seven in 2/61 (3.3%) VWD2M patients (P < 0.0001).
CONCLUSION: Bleeding tendency in VWD2A is greater than that of VWD2M, is not explained by factor VIII or VWF levels and is mainly due to an increased incidence of gastrointestinal bleeding.
© 2012 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22329792     DOI: 10.1111/j.1538-7836.2012.04661.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  33 in total

Review 1.  Current challenges in the diagnosis and management of patients with inherited von Willebrand's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis.

Authors:  Piercarla Schinco; Giancarlo Castaman; Antonio Coppola; Dorina Cultrera; Cosimo Ettorre; Anna C Giuffrida; Emanuela Marchesini; Renato Marino; Marta Milan; Claudio Molinari; Simona M Siboni; Ezio Zanon; Augusto B Federici
Journal:  Blood Transfus       Date:  2017-05-26       Impact factor: 3.443

2.  Crucial role for the VWF A1 domain in binding to type IV collagen.

Authors:  Veronica H Flood; Abraham C Schlauderaff; Sandra L Haberichter; Tricia L Slobodianuk; Paula M Jacobi; Daniel B Bellissimo; Pamela A Christopherson; Kenneth D Friedman; Joan Cox Gill; Raymond G Hoffmann; Robert R Montgomery
Journal:  Blood       Date:  2015-02-06       Impact factor: 22.113

Review 3.  Advances in the diagnosis and treatment of Von Willebrand disease.

Authors:  Ruchika Sharma; Veronica H Flood
Journal:  Blood       Date:  2017-11-30       Impact factor: 22.113

Review 4.  Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science.

Authors:  Soundarya Selvam; Paula James
Journal:  Semin Thromb Hemost       Date:  2017-05-05       Impact factor: 4.180

5.  von Willebrand factor binding to myosin assists in coagulation.

Authors:  Veronica H Flood; Tricia L Slobodianuk; Daniel Keesler; Hannah K Lohmeier; Scot Fahs; Liyun Zhang; Pippa Simpson; Robert R Montgomery
Journal:  Blood Adv       Date:  2020-01-14

Review 6.  Advances in the diagnosis and treatment of Von Willebrand disease.

Authors:  Ruchika Sharma; Veronica H Flood
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

7.  New therapies for von Willebrand disease.

Authors:  Pier Mannuccio Mannucci
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

8.  Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.

Authors:  D M Larsen; S L Haberichter; J C Gill; A D Shapiro; V H Flood
Journal:  Haemophilia       Date:  2013-03-18       Impact factor: 4.287

Review 9.  The molecular characterization of von Willebrand disease: good in parts.

Authors:  P D James; D Lillicrap
Journal:  Br J Haematol       Date:  2013-02-14       Impact factor: 6.998

10.  Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.

Authors:  Joan C Gill; Giancarlo Castaman; Jerzy Windyga; Peter Kouides; Margaret Ragni; Frank W G Leebeek; Ortrun Obermann-Slupetzky; Miranda Chapman; Sandor Fritsch; Borislava G Pavlova; Isabella Presch; Bruce Ewenstein
Journal:  Blood       Date:  2015-08-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.